Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

[1]  Y. Pekarsky,et al.  FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. , 1999, Cancer research.

[2]  C. Croce,et al.  Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Huebner,et al.  The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. , 1999, Cancer research.

[4]  C. Croce,et al.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions. , 1998, Cancer research.

[5]  M. Rugge,et al.  Loss of FHIT expression in gastric carcinoma. , 1998, Cancer research.

[6]  Y. Pekarsky,et al.  Absence or reduction of Fhit expression in most clear cell renal carcinomas. , 1998, Cancer research.

[7]  C. Reznikoff,et al.  Minimal deletion of 3p13→14.2 associated with immortalization of human uroepithelial cells , 1998, Genes, chromosomes & cancer.

[8]  C. Croce,et al.  Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[10]  Kathleen R. Cho,et al.  Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. , 1997, Cancer research.

[11]  G. Giaccone,et al.  FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. , 1997, Cancer research.

[12]  C. Croce,et al.  Structure and expression of the human FHIT gene in normal and tumor cells. , 1997, Cancer research.

[13]  K. Yanagisawa,et al.  Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. , 1996, Cancer research.

[14]  F. Sarkar,et al.  Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. , 1996, Cancer research.

[15]  L. D. Barnes,et al.  Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. , 1996, Biochemistry.

[16]  C. Cordon-Cardo,et al.  Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. , 1996, The American journal of pathology.

[17]  R. Espinosa,et al.  Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2. , 1996, Genomics.

[18]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[19]  M. Rugge,et al.  Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. , 1996, Cancer research.

[20]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[21]  T. Glover,et al.  FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. , 1996, Human molecular genetics.

[22]  D. Sidransky,et al.  Evidence for two bladder cancer suppressor loci on human chromosome 9. , 1993, Cancer research.

[23]  S. Lerner,et al.  Role of chromosome 9 in human bladder cancer. , 1993, Cancer research.

[24]  E. Crawford,et al.  Current management of invasive and metastatic transitional cell carcinoma of the bladder. , 1993, The Journal of urology.

[25]  M. Knowles,et al.  Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. , 1993, Cancer research.

[26]  W. Benedict,et al.  Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression , 1993, International journal of cancer.

[27]  M. Knowles,et al.  Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. , 1991, Oncogene.

[28]  C. Cordon-Cardo,et al.  Molecular genetic alterations in superficial and locally advanced human bladder cancer. , 1991, Cancer research.

[29]  D. Neal,et al.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. , 1991, British Journal of Cancer.

[30]  P. Nichols,et al.  Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. , 1990, Cancer research.

[31]  Tnm.  The tnm classification of malignant tumors , 1988 .

[32]  S. Jacobs,et al.  Hereditary renal-cell carcinoma associated with a chromosomal translocation. , 1979, The New England journal of medicine.

[33]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[34]  P. Jones,et al.  Bladder cancer epidemiology and pathogenesis. , 1996, Seminars in oncology.

[35]  P. Lichter,et al.  Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. , 1995, The American journal of pathology.

[36]  J. Rhim,et al.  Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours , 1984, Nature.

[37]  藤田 潤.  Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours , 1984 .

[38]  N. Dubrawsky.  Cancer statistics , 2022 .